Preface

Dear readers,

With “memo inOncology” Springer has created a medical education platform that is globally accessible and offers value to health care professionals in oncology (www.memoinoncology.com).

Over the last four years, we have reported from major conferences such as ASCO, ESMO, WCLC, ELCC or ESMO Asia on recent highlights in the field of lung cancer. Our congress reports and translations thereof into Mandarin and Japanese have received great international interest. Hence, we have decided to expand on this success and create additional content on other solid tumors. This issue covers novel clinical research on anti-PD-1 treatment, a potential role of the microbiome in tumorigenesis as well as PARP inhibition in gynecological cancers and beyond. We hope that you will enjoy reading this report and find it useful.

Dr. Alois Sillaber
Managing Director
Springer-Verlag GmbH
Springer Nature

More posts

New applications of PARP inhibitors

Metastatic castration-resistant prostate cancer (mCRPC) that progresses after androgen-receptor(AR)–targeted therapy (i.e., enzalutamide or abiraterone) and taxane-based chemotherapy is associated with a poor prognosis [1]. Only few treatment options are available for these patients.

PARP inhibition in gynecological cancers: recent insights

Poly(ADP-ribose) polymerase (PARP) inhibitors have been established as an important drug class for the treatment of advanced ovarian cancer (OC), which is a leading cause of cancer deaths in women. Olaparib and niraparib have been widely approved for maintenance treatment of OC patients who responded to platinum-based chemotherapy.

Potential role of the microbiome in carcinogenesis and response to checkpoint inhibition

Bacteria are of eminent importance for health and the functioning of the human body that contains more bacterial than human cells, at a ratio of 1.3 to 1. More than 10,000 different microbe species have been identified in the body. Ten to 100 trillion symbiotic microbial cells are harbored by each individual, primarily in the gut.

Preface

With “memo inOncology” Springer has created a medical education platform that is globally accessible and offers value to health care professionals in oncology (www.memoinoncology.com). Over the last four years, we have reported from major conferences such as ASCO, ESMO, WCLC, ELCC or ESMO Asia on recent highlights in the field of lung cancer.